DigestRedComo funciona
Red
/
Empresas
Am
No verificado

Amphista Therapeutics

Sobre qué escribimos

Anuncios brevesBiotecnologíaMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

17 Comunicados de prensa

Ver todos los comunicados de prensa
24/04/2026
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Medicina Salud Bienestar
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
20/04/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Amphista Therapeutics presents the discovery, characterisation and chemical structure of AMX-883, an orally bioavailable, highly potent and selective DCAF16 degrader of BRD9 at AACR 2026
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
23/03/2026
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics announces three presentations at the American Association for Cancer Research Annual Meeting on its next-generation Targeted Glue™ degrader programs
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
18/03/2026
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics appoints Louise Modis Ph.D. as CEO and Patrick Kelly M.D. as CMO and provides a business update as the Company prepares to file IND application for AMX-883
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
26/02/2026
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys® platform is delivering Targeted Glue™ degraders using novel E3 ligases into the clinic
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
07/12/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
25/11/2025
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics announces new AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
28/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics to showcase how its Targeted Glue™ technology is expanding the diversity of TPD medicines at the 8th Annual TPD & Induced Proximity Summit 2025
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
27/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0
23/10/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Amphista Therapeutics announces three key strategic leadership appointments to drive transition of its Targeted Glue™ protein degraders into clinical development
Fuente
Amphista Therapeutics
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0